Efficacy and safety of adamgammadex for reversing rocuronium-induced deep neuromuscular block: a multicentre, randomised, double-blind, positive-controlled phase III trial
Primary resultResult — go to the resultDifference −1.3% 95% CI −4.6% to 1.2%Authors' conclusion
Adamgammadex was noninferior to sugammadex in reversing deep neuromuscular block from rocuronium.
Study context
- Population
- Patients with deep rocuronium-induced NMB
- Participants
- 321 patients
- Comparison
- Adamgammadex 8 mg kg-1 vs sugammadex 4 mg kg-1
- Primary endpoint
- Success rate of antagonism (recovery of TOFR to 0.9)
- Follow-up
- Within 10 min
Methodological detailsmulticentre, double-blind, positive-controlled, noninferiority, phase III
- Multicentre
- Double-blind
- Positive-controlled
- Noninferiority
- Phase III
Primary result
As reported in the abstract
Difference
−1.3%
95% CI −4.6% to 1.2%
By group
Adamgammadex vs Sugammadex
difference −1.3% (95% CI −4.6% to 1.2%)
Secondary outcomes
Median, min
| Outcome | Adamgammadex | Sugammadex | Difference (min) (95% CI) | |
|---|---|---|---|---|
| Time to recovery of TOFR to 0.9 (key secondary) | 2.5 (IQR 2.0–3.2) | 2.2 (IQR 1.7–2.7) | 0.5 (0.3–0.7) | |
| −0.500.51Difference, min (linear scale) |
- Time to recovery of train-of-four ratio (TOFR) to 0.9 (key secondary): upper limit 0.7 min lower than noninferiority margin of 5 min
- Time to recovery of TOFR to 0.9 (key secondary): noninferiority margin 5 min
Other secondary efficacy outcomes
- No inferiority in secondary efficacy outcomes
Safety
Safety profile
- No significant difference between adamgammadex and sugammadex
Original publication
Efficacy and safety of adamgammadex for reversing rocuronium-induced deep neuromuscular block: a multicentre, randomised, double-blind, positive-controlled phase III trial. Br J Anaesth. Published 2 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →